Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cisplatinum compounds]

K Ota1

  • 1Nagoya Memorial Hospital.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

New platinum-based chemotherapy drugs, 254-S and DWA2114R, show similar anti-cancer effects to cisplatin but with reduced side effects like nausea. These agents may improve patient quality of life during cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Experimental and clinical studies on dysregulation of magnesium metabolism and the aetiopathogenesis of multiple sclerosis.

Magnesium research·1992
Same author

Mechanism of proteinuria in nephrotic syndrome.

Acta medica Okayama·1992
Same author

Effects of nicergoline on calcium and magnesium deposition in the central nervous system tissues of rats maintained on low-calcium diets.

The Journal of international medical research·1992
Same author

Alpha 2-adrenergic receptors are involved in the suppression of luteinizing hormone release during acute fasting in the ovariectomized estradiol-primed rats.

Neuroendocrinology·1992
Same author

[Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo].

Gan to kagaku ryoho. Cancer & chemotherapy·1992
Same author

[Anti-emetic effect and safety of ondansetron tablet in double-blind comparison with placebo].

Gan to kagaku ryoho. Cancer & chemotherapy·1992
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Cisplatin is a widely used chemotherapy agent for various cancers.
  • Cisplatin treatment is associated with significant toxicities, including nephrotoxicity, nausea, and vomiting.
  • Development of novel platinum derivatives aims to improve efficacy and reduce adverse effects.

Purpose of the Study:

  • To review new cisplatin derivatives (254-S, DWA2114R, NK121) developed in Japan.
  • To compare the efficacy and toxicity profiles of these derivatives against cisplatin.
  • To assess the potential of these derivatives to improve patient quality of life (QOL).

Main Methods:

  • Review of preclinical and clinical data for 254-S, DWA2114R, and NK121.
  • Randomized controlled studies comparing 254-S (non-small-cell lung cancer) and DWA2114R (ovarian cancer) against cisplatin.

Related Experiment Videos

  • Evaluation of antitumor activity, nephrotoxicity, nausea/vomiting, myelotoxicity, and hydration requirements.

    • Main Results:

    • 254-S and DWA2114R demonstrated comparable antitumor activity to cisplatin.
    • These derivatives exhibited less nephrotoxicity and nausea/vomiting compared to cisplatin, but increased myelotoxicity.
    • Randomized studies showed similar efficacy but significantly less hydration needs for 254-S and DWA2114R.

    Conclusions:

    • Cisplatin derivatives 254-S and DWA2114R offer comparable antitumor efficacy to cisplatin with a potentially improved toxicity profile.
    • Reduced nephrotoxicity and nausea/vomiting suggest these agents may enhance patient QOL.
    • Further investigation, including NK121's phase II study, is warranted for these novel platinum compounds.